Changes in Multiparametric MRI Parameters Following Stereotactic Ablative Radiotherapy in Early Stage Non-Small Cell Lung Cancer: Pilot Study

SUMMARY

You have been asked to participate in this research study because you have lung cancer and will be treated with Stereotactic Ablative Radiotherapy (SABR).  This is a technique of sophisticated external beam radiation delivery where higher radiation doses are directed to the tumor over 1-1.5 weeks.  The purpose of this study is to evaluate any changes seen in the multiparametric Magnetic Resonance Imaging (mMRI) scans taken during and after SABR treatment (for up to 3 months following treatment) and to study if early changes seen on MRI can be helpful in determining your response to treatment. Your participation in this study is expected to last approximately 3 months and you will be followed up to three (3) years for the purposes of obtaining surveillance computed tomography (CT) scans as part of the standard of care.

Magnetic Resonance Imaging (MRI) is a tool that is widely used for cancer imaging.  MRI is a technique that uses magnets, radiowaves and a computer to create a picture of the internal body.  A substance called a contrast agent is injected into the blood.  The agent signals or lights up the blood flow in the body.  Several images are taken over a certain amount of time.  These pictures or scans are often taken during and after cancer treatment.  The scans are used to view the tumor and to take measurements of the size and determine if the tumor is smaller, bigger or the same size during and after treatment for cancer.  There is no ionizing or harmful radiation being delivered during this scan.

In other cancer sites, mMRI is being developed to monitor response to a patient’s treatment and is demonstrating promising results.  It is proposed that mMRI can provide superior information regarding response to cancer treatment compared to traditional CT scans, but this has not been fully studied. mMRI is a more sophisticated technique of performing MRI scans in that additional information is being acquired to study the cancer.  There is no additional contrast being given to you to do this type of scan compared to a regular MRI with contrast. The mMRI will feel the same as a regular MRI scan, but can take several minutes longer.

This research study is to find important information on the ability of MRI to follow changes in the lung cancer after SABR.  With this information, mMRI will be developed further to follow lung cancer patients and may eventually lead to a new way for monitoring response to SABR for future patients.

COH Protocol Number : 13260

Principal Investigator : Sampath, Sagus M.D.

Sponsor : City of Hope

BRIEF ELIGIBILITY CRITERIA :

Eligible Ages : >=18

Gender : Either

Prior Chemotherapy :

Brain Metastases :

Measurable Disease :